Mitochondrial Rho GTPase 1 (RHOT1) (RHOT1)

Mitochondrial Rho GTPase 1 (RHOT1), widely known as MIRO1, is a tail-anchored protein on the outer mitochondrial membrane that plays a pivotal role in mitochondrial motility and quality control (UniProt Q8IXI2). It functions as a molecular bridge between mitochondria and motor proteins, such as kinesin and dynein, enabling the transport of mitochondria along microtubules to meet local energy demands (PubMed: 21183606). MIRO1 is uniquely characterized by two GTPase domains and two calcium-binding EF-hand motifs, which allow it to halt mitochondrial transport in response to elevated intracellular calcium levels (PubMed: 19234454). In Parkinson's disease, the failure to degrade MIRO1 from damaged mitochondria is a significant pathological feature, as it prevents the initiation of mitophagy and leads to the accumulation of dysfunctional organelles (PubMed: 31561197). This defect in MIRO1 degradation has been observed in both sporadic and familial cases of Parkinson's, making it a potential universal biomarker for the disease. Consequently, MIRO1 is being investigated as a therapeutic target, with research focusing on small-molecule Miro1 reducers that promote its degradation to restore mitochondrial health and protect dopaminergic neurons (Nature Communications, 2019). Beyond neurodegeneration, MIRO1 has also been implicated in cancer progression, where it may facilitate the metabolic adaptation of tumor cells by modulating mitochondrial distribution. Therapeutic challenges include ensuring the specificity of Miro1-targeting agents to avoid disrupting essential mitochondrial functions in healthy tissues.

Other names

MIRO1Miro-1Ras homolog family member T1ARHT1

Promotion of Miro1 degradation to facilitate mitophagy and clearance of damaged mitochondria